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Summary
 
Cytomegalovirus (CMV) is generally described as a slowly replicating virus. During studies of
immunocompromised patients, we observed rapid changes in the quantity of CMV DNA
present in serial blood samples by quantitative-competitive polymerase chain reaction com-
mensurate with a doubling time of 
 
,
 
2 d. To further investigate the dynamics of replication in
vivo, patients in three distinct situations were studied in detail: (a) those receiving intravenous
ganciclovir; (b) those in whom ganciclovir-resistant strains appeared during long-term therapy;
and (c) those in whom ganciclovir-resistant strains disappeared with alternative drug therapy. In
all cases, it was possible to provide accurate estimates of the doubling time of CMV and its half-
life of disappearance after antiviral chemotherapy. The results from all three approaches dem-
onstrated that the doubling time/half-life of CMV in blood is 
 
z
 
1 d when frequent samples are
collected. These results show that CMV DNA replication in vivo is a highly dynamic process.
We conclude that the reputation of CMV as a slowly replicating virus based on the time taken
to produce cytopathic effects in vitro is unwarranted. These findings have implications for the
potency, dose, and duration of antiviral chemotherapy needed for the effective treatment of
this important human pathogen.
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H
 
uman CMV, a member of the 
 
Betaherpesvirinae
 
, infects
 
z
 
60% of individuals in the developed world and 
 
.
 
90%
of individuals in the developing world (1). In the immuno-
competent individual, infection is usually asymptomatic, but
in hosts whose immunity is impaired, such as the neonate,
the transplant recipient, or HIV-infected individuals, the full
pathogenic potential of the virus may be realized (1). Dis-
eases associated with CMV infection include pneumonitis,
hepatitis, gastrointestinal tract disease, and retinitis.
CMV has been generally regarded as a slowly replicating
virus on the basis of time to appearance of cytopathic effect in
cell culture, especially when compared with other members
of the 
 
Herpesviridae
 
 such as herpes simplex virus type 1 (2).
Studies to date in humans suggest that, after initial infection,
CMV remains in a latent state in monocytes, and recent data
have shown that allogeneic stimulation of monocytes from
CMV-seropositive individuals can lead to viral replication
and viral antigen expression (3). In the immunocompromised
host, infection with CMV strains from the donor organ (4, 5)
or reactivation of recipient strains (6) can occur leading to in-
creases in viral load in the blood and commensurate disease
development. Our group, among others, has shown in longi-
tudinal analyses of transplant recipients and AIDS patients that
CMV load is an important parameter in pathogenesis, such
that symptomatic patients have a consistently higher median
viral load than asymptomatic individuals (7–10). Further-
more, multivariate statistical models demonstrate that previ-
ously recognized risk factors for disease, such as CMV serosta-
tus of the donor and recipient, are explained through elevated
viral load in the posttransplant period (7–9).
During these investigations, we observed that CMV loads
increased markedly during active infection of immuno-
compromised hosts and wished to ascertain the dynamics of
viral replication in vivo. Using an approach that recently
defined the highly dynamic nature of HIV and particularly
hepatitis C virus (HCV)
 
1
 
 replication (11–13), we exploited
the ability of potent antiviral intervention to perturb the
host–virus equilibrium, together with population dynamics
(14), to provide for the first time an estimate of the doubling
time of CMV in the human host. Since estimates derived
from one strategy could be misleading, we used two further
approaches to obtain estimates of the dynamics of CMV
replication in vivo; all of these results concur and indicate
 
1
 
Abbreviations used in this paper:
 
 GCV, ganciclovir; HCV, hepatitis C virus;
HPMPC, cidofovir; PMA, point mutation assay. 
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that CMV replicates dynamically in the immunocompro-
mised host.
 
Materials and Methods
 
Patients Investigated
 
The results calculated have come from detailed investigations
of patient cohorts whose clinical features have been described
elsewhere (8, 9, 15, 16).
 
Extraction of CMV DNA and PCR Conditions
 
DNA was extracted from whole blood samples (200 
 
m
 
l) using
ion exchange chromatography with a Qiagen DNA extraction
kit according to the manufacturer’s instructions. Primers directed
towards the CMV glycoprotein B (UL55) gene were used for the
qualitative and quantitative detection of CMV and have been de-
scribed in detail elsewhere (17). The quantitative-competitive PCR
method for assessing CMV load used an internal control sequence
consisting of a mutagenized version of the 149-bp authentic tar-
get sequence. The details of this method have been described ex-
tensively elsewhere (7–9, 18). The lowest level of detection in
these assays is 200 genomes/ml blood.
 
Detection of UL97 Mutants in Clinical Samples
 
The following primers were used for the amplification of UL97:
primer 1, (outer) 5
 
9
 
 AGACGGTGCTACGGTCTGGATGT;
primer 2, (outer) 5
 
9
 
 GTTTGTACCTTCTCTGTTGCCTTT;
and the nested primers: primer 3, (inner) 5
 
9
 
 CAACGTCACGG-
TACATCGACGTTT; primer 4, (inner) 5
 
9
 
 GCCATGCTCGC-
CCAGGAGACAGG.
The nested amplification was performed using conditions de-
scribed previously (19) and yielded a 700-bp amplicon.
The microtiter point mutation assay (PMA) for the detection
of UL97 mutations at codons 460, 520, 594, and 595 has been
described in detail elsewhere (19).
 
Analysis of Results
 
Response of CMV Load to Ganciclovir Therapy.
 
The basic mod-
els used for viral dynamics of CMV are similar to those described
for HIV (11–13, 20–22). Assuming that virus DNA levels in blood
after therapy with ganciclovir (GCV) decline according to an ex-
ponential function, the slope of decline can be used to calculate
the rate of viral clearance in blood. If the system is in equilibrium
at initiation of therapy with the rate of viral production equal to
the rate of viral clearance, then after therapy with a drug that to-
tally blocks viral production, the dynamics of GCV is given by
 
y
 
(0)
 
e
 
2
 
at
 
, where 
 
y
 
(0) is the initial viral load and 
 
a
 
 is the viral clear-
ance rate constant. Plotting the change in CMV viral load with
time followed by computation of the slope of decline after initia-
tion of GCV therapy allows the half-life of virus in the blood to
be calculated according to the formula 
 
t
 
1/2
 
 = 
 
2
 
ln2/slope.
 
Fitness of UL97 Variants and Generation Time.
 
The relative fit-
ness, 
 
s
 
, of the population (in this case, different UL97 variants)
was calculated from the following equation, which assumes replica-
tion occurs in continuous time (23). This equation merely requires
knowledge of the relative proportion of the most fit variant (
 
p
 
)
and the least fit variant (
 
q
 
) at times 0 and 
 
t
 
, respectively. These
quantitative parameters were obtained from the PMA described
above.
 
(1) s 1
t
--
qt () p 0 ()
pt () q 0 ()
---------------------------- ln =
 
In some cases, the proportions of the genotypes in the 
 
p
 
(0) or
 
q
 
(0) category were below the detection limit of the PMA, and so
this value was estimated to calculate the relative fitness gain of
mutant virus in the presence of GCV. In such cases, different es-
timates for the proportion of mutant genotypes were used but
generally did not substantially affect the calculated fitness gain.
Simulated repopulation curves of wild-type or mutant UL97
genotypes were generated by computing the proportion of 
 
p
 
(
 
t
 
) at
daily intervals with different starting populations of 
 
q
 
.
 
Results
 
Decay Rates of CMV DNA after Antiviral Intervention
 
The first approach to assess the dynamics of viral replica-
tion was to perturb the host–viral equilibrium by introduc-
ing a potent inhibitor of replication and then to determine
the rate of decline of virus in the host. Initially, we used data
from 35 AIDS patients with first episode CMV retinitis who
received intravenous GCV therapy for 21 d. The median
CMV load in these patients at baseline was 4.95 log
 
10
 
genomes/ml and by day 21 the majority of patients had lev-
els of CMV DNA below the sensitivity of the assay (
 
,
 
200
genomes/ml; see Fig. 1) corresponding to a mean decrease
of 
 
2
 
2.46 logs. Thus, calculation of the half-life of clearance
in these patients provided a conservative (upper) estimate of
the half-life of decline of CMV in blood of 2.56 
 
6 
 
0.36 d.
To obtain further estimates for the decline of CMV
DNA after GCV intervention, we performed similar analy-
ses in bone marrow transplant recipients (
 
n 
 
= 11) and liver
transplant recipients (
 
n
 
 = 13) with active CMV infection.
The half-life of decline of viral DNA in the blood of these
patient groups after intravenous GCV therapy was 1.52 
 
6
 
0.67 d for the bone marrow recipients and 2.36 
 
6 
 
1.2 d for
the liver transplant recipients (data not shown).
Further refinement of the half-life of decline of CMV
DNA in blood was achieved by enrolling five AIDS pa-
tients with CMV retinitis into an intravenous GCV induc-
tion study that involved frequent sampling (median of five
Figure 1. Log reduction in CMV load in the blood of 35 AIDS retinitis
patients during 21 d of induction therapy with intravenous GCV (5 mg/
kg/bd). CI, confidence interval. 
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samples per patient over 21 d of therapy). The CMV load
modulations in these patients are shown in Fig. 2, together
with the slope of decline of viral load. The average half-life
of decline of CMV in the blood of these patients was 0.98 
 
6
 
0.3 d. A similar estimate was obtained for the decline of
CMV DNA in the urine (0.96 
 
6
 
 0.14 d; data not shown).
The advantage of performing these detailed studies in the
HIV-infected host relates to their relatively stable CMV
DNA load (mean difference between samples before ther-
apy 0.2 log
 
10 
 
genomes/ml)
 
 
 
in the month preceding therapy,
i.e., they fulfill the requirement for a steady state to be
present at the initiation of therapy.
 
Kinetics of CMV Synthesis In Vivo
 
To provide a direct estimate of the doubling time of CMV
in vivo, we studied a group of bone marrow transplant pa-
tients in whom frequent surveillance samples (median sam-
pling time once per week) were collected after transplant
and in whom CMV DNA appeared and increased in level.
CMV load in the blood of 18 patients was analyzed (Fig. 3),
and the mean doubling time of CMV in the blood was cal-
culated as 2.09 
 
6
 
 1.33 d (median 1.5 d, range 0.38–4.7).
 
Population Dynamics of Wild-type and Mutant Forms of CMV 
in the UL97 Gene after Antiviral Therapy
 
We next examined the genotypic composition of the
CMV UL97 gene in AIDS patients receiving long-term
antiviral therapy. Calculation of the relative fitness of mutant
and wild-type virus requires a method to quantitate the rela-
tive distribution of wild-type and mutant virus present
within an evolving population (see Materials and Methods).
We have developed a PMA for the most frequently observed
mutations in UL97 and used the data to determine the rela-
tive fitness of drug-resistant and wild-type virus.
 
Appearance of Drug-resistant UL97 Mutants.
 
10 AIDS pa-
tients treated with GCV were investigated longitudinally
for the appearance of alterations in the genotypic composi-
tion of UL97 by the PMA. We calculated the relative fitness
gain of the mutant UL97 population over the wild-type
population using a standard formula for the effects of selec-
tion at a single locus in an asexual haploid population, as
previously used for calculations of relative fitness of HIV
drug-resistant mutations. Assuming replication in continu-
ous time, the selection coefficient 
 
s
 
 is given by equation 1
in Materials and Methods.
 
Reappearance of Wild-type UL97 Genotypes.
 
In addition
to the 10 patients in whom the fitness gain of mutant virus
was calculated, we also obtained samples from patients who
had been exposed to GCV, had developed high-level geno-
typic resistance in UL97, and who were then given cido-
fovir (HPMPC) therapy. Since HPMPC is a phosphonate
which does not require UL97 for activation, there would
be no growth advantage for CMV strains with GCV-resis-
tant UL97 genotypes. Consequently, in a mixed population,
the wild-type UL97 genotype should repopulate at the ex-
pense of the mutant genotype if the virus carrying the mutant
genotype is less fit. We analyzed three patients prescribed
GCV followed by HPMPC and calculated the relative fit-
ness gain of wild-type UL97 virus compared with mutant
UL97 virus. A representative picture of the repopulation
Figure 2. Reduction in CMV load in the blood of five AIDS retinitis patients subjected to intensive sampling after initiation of intravenous GCV ther-
apy. The data points are represented as filled circles, and the computed line of best fit is shown. 
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rates of wild-type virus after HPMPC therapy is shown in
Fig. 4. Similar repopulation plots were generated for all the
patients under consideration.
The results generated by the analysis summarized above
are shown in Table I. The fitness gain of CMV strains car-
rying UL97 mutations associated with GCV resistance in
the presence of GCV ranged from 2.6% for the double mu-
tant A594V + M460I to 9% for L595S. Indeed, the consis-
tency of estimates was demonstrated for the L595F muta-
tion, where the three patients investigated produced values
of 3.9, 5.3, and 5.9% relative fitness gain. In patients whose
therapy was changed from GCV to HPMPC, the relative
fitness gain of wild-type viral genotypes was comparable,
ranging from 3.5% for the L595S mutation to 12.8% for
the double mutant M460I + L595F. 
 
Discussion
 
To date, there have been no estimates of the replication
rate of CMV in the human host. To gain insight into CMV
replication in vivo, we used three approaches which have
been extensively applied to ascertain the dynamics of HIV
and HCV (11–14, 20–22). First, we assessed the rate of de-
cline of CMV in the blood after GCV therapy in AIDS
patients, liver transplant, and bone marrow transplant re-
cipients. GCV is a potent inhibitor of the viral DNA poly-
merase and thus inhibits formation of new virus particles
(24). The computed upper estimate of the half-life of virus in
the blood was between 1.5 and 2 d. In a dynamic situation,
the accuracy of these half-life estimates partially reflects the
frequency of sampling; therefore, we performed frequent
viral load measures in the blood of five AIDS patients, and
the results refined the estimated half-life of the virus in the
blood to 
 
z
 
1 d. Since GCV is unlikely to be 100% effective
at inhibiting replication, this estimate is likely to be a mini-
mal one and parallels the data recently presented for HCV
responses after IFN therapy (13).
 
 
 
The second approach used
the direct assessment of viral load kinetics in bone marrow
transplant patients undergoing active infection. The results,
albeit limited by the frequency of sampling, indicated that
the doubling time of CMV in the blood was 
 
z
 
2 d. The
third approach exploited the kinetics of appearance of dif-
ferent genotypes as a consequence of the growth advantage
provided to drug-resistant variants in the presence of selec-
tive drug pressure or to wild-type variants when the selec-
tive pressure was removed. Taken together, these approaches
have shown that CMV replication in vivo is a highly dy-
namic process and likely proceeds with a doubling time of
 
z
 
1 d.
The highly dynamic nature of certain human viral infec-
tions such as HIV, HCV, and HBV has been established us-
ing similar approaches and assumptions to those used in this
study (11–14, 20–22, 25). The half-life of CMV in the blood
Figure 3. Rate of increase in CMV load in the blood of 18 bone mar-
row transplant recipients after allogeneic transplantation.
Figure 4. Simulated repopulation rates of wild-type UL97 CMV
strains for the mutation L595S. The proportion of wild-type is shown for
three different starting populations of wild-type genotype (1% [solid line],
5% [dashed line], and 10% [broken line] corresponding to q(0) of 0.01,
0.05, and 0.1, respectively) at the initiation of HPMPC therapy. The re-
sults from the PMA are shown as filled squares.
 
Table I.
 
Relative Fitness of Mutant and Wild-type UL97 Viruses 
after Initiation of Ganciclovir Therapy (Patients 1–10) or HPMPC 
Therapy (Patients 11–13)
 
Patient Mutation Relative fitness gain
Mutant vs. wild-type (
 
%
 
)
1 L595F 3.9
2 L595F 5.6
3 L595F 5.3
4 L595S 9.0
5 L595S 8.0
6 M460V 3.7
7 M460I 4.8
8 H520Q 5.0
9 A594V 
 
1
 
 M460I 2.6
10 L595F 
 
1
 
 M460I 7.5
Wild-type vs. mutant
11 L595S 3.5
12 L595F 5.6
13 M460I 
 
1
 
 L595F 12.8 
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is more similar to the half-life of the HIV-infected lympho-
cyte (mean 
 
t
 
1/2
 
 = 2 d) than the HBV- or HCV-infected
hepatocyte (
 
t
 
1/2
 
 = 10–100 d). Immune clearance mecha-
nisms, including lysis of infected cells by cytotoxic T lym-
phocytes, have been implicated in the clearance of HIV-
1–infected lymphocytes (22) and can be invoked to account
for the clearance of CMV-infected cells after GCV therapy
(26). However, other nonspecific immune clearance mecha-
nisms may also be instrumental in removing the CMV-
infected cells. Comparison of the dynamics of CMV repli-
cation in different patient groups should provide insight
into the immunologic control mechanisms operational in
each host and help elucidate the relative contributions of
population dynamics and immune control to preventing
CMV disease.
The quantitative distribution of wild-type and mutant
alleles determined by the PMA was crucial to assess the fit-
ness of UL97 variants under GCV selection and the repop-
ulation rates of wild-type strains after change of therapy to
HPMPC, which does not require UL97 for activation (27).
Importantly, none of the strains investigated had drug-resis-
tant mutations in the UL54 gene (data not shown), and so
we are confident that the fitness differences observed reside
within the UL97 gene.
 
 
 
In AIDS patients, CMV retinitis usu-
ally occurs after an extensive period of active replication (28,
29) in which many variants may be produced. The dynam-
ics of resistance have been succinctly described for HIV by
Bonhoeffer et al. (22) and are directly relevant to the dy-
namics of CMV resistance. The expected pretherapy fre-
quency of mutants depends upon the number of point mu-
tations between wild-type and mutant virus, the mutation
rate associated with virus replication, the relative replication
rates of wild-type virus and resistant virus, and the popu-
lation size. In the case of CMV UL97 mutants, the majority
of resistance mutations involve single point mutations (30, 31)
and are frequently observed in AIDS patients on long-term
GCV therapy in whom substantial replication will have oc-
curred before antiviral intervention. Although the mutation
rate of the CMV DNA polymerase is much lower than
HIV reverse transcriptase, the population size at initiation of
therapy is large and so, perhaps not surprisingly, we found
evidence for small but reproducible amounts of mutant vi-
rus present at baseline, i.e., before GCV therapy. Therefore,
we surmise that mutants at the UL97 loci are present within
the population at a low frequency before therapy rather
than generated during therapy. This may help to explain
why a high frequency (70%) of AIDS patients who experi-
ence CMV viremia during therapy with GCV have evi-
dence of UL97 mutations (16).
The relatively rapid replication rate of CMV in vivo ap-
pears to contrast with the dogma from in vitro experiments
that CMV is a slowly replicating virus (2). This conclusion
was reached many years ago and was based on the time to
appearance of cytopathic effect and release of virions, and
our data question the relevance of these observations to the
in vivo situation.
In conclusion, the long-standing reputation of CMV as a
slowly replicating virus requires reappraisal in light of mod-
ern molecular approaches to quantitate DNA replication.
Certainly, the time to appearance of cytopathic effect in vitro
is long, but this must be due to factors other than a slow
DNA replicative cycle. The finding that CMV replication in
vivo is a highly dynamic process has profound implications
for the potency, dose, and duration of antiviral therapy re-
quired to control CMV; we suggest that the concepts (32)
recently gleaned from the study of HIV should be applied
to CMV.
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